UroGen Pharmaceuticals Ltd has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of 1,135,847 shares priced at $44.02 a unit to raise $50m.
Based in Israel, UroGen is involved in developing uro-oncology drugs and urological pathologies.
Underwriters will be granted a 30-day option to purchase additional 170,377 ordinary shares.
The company expects to receive approximately $46.3m from the offering, after deducting the underwriting discounts and commissions.
Proceeds are intended to be used for the completion of the single pivotal phase III clinical trial of MitoGel, and its commercial launch upon approval.
A proportion of funds will be used for initiating a Phase IIb clinical trial on VesiGel and to file an investigational new drug (IND) application for the treatment of low-grade NMIBC.
Remaining proceeds will be used for continued research and clinical development of other product candidates, including Vesimune, as well as for working capital and other general corporate purposes.
Pherecydes Pharma SA has raised €8.7m ($10.65m) in a series B financing round.
Go Capital along with Omnes Capital SAS, Fa Diese and a group of business angels from the Rhone-Alpes region and historical investors ACE Management, Auriga Partners and Participations Besancon participated in the round.
Based in France, Pherecydes is involved in the research and development of anti-infective therapies. It intends to use proceeds to manufacture phages for compassionate use temporary authorisation for use compliant with GMP.
Remaining proceeds will be used for establishing a 10,000ft² pharmaceutical production unit at Nantes, to launch new clinical research programmes, and to move two programmes into clinical phase in 2018 and 2019.
Tiziana Life Sciences Plc has raised £150,000 ($210,000) through a private placement of shares.
The transaction involved placement of 100,000 new ordinary shares each priced at £1.50 ($2.06).
Each share also includes a warrant, which entitles the holder to subscribe for one more new ordinary share at a price of £1.60 ($2.20) a share on or before 15 January 2024.
Genocea Biosciences Inc has announced a public offering of shares of its common stock and class A warrants to purchase shares of common stock in order to raise funds to support its ongoing clinical development programmes, supplement working capital, and general corporate purposes.
Underwriters will be granted a 30-day option to purchase additional shares of common stock and/or class A warrants, which will be equal to 15% of the number of securities sold.
Warrants can be exercised within five years of the issue date.
Based in the US, Genocea Biosciences is a cancer vaccines discovery and development company.
US-based clinical-stage gene therapy company AveXis Inc has announced the pricing for its proposed public offering of 3,921,600 shares of its common stock.
The shares are priced at $102 each and will raise approximately $400m in gross proceeds for the company.
Underwriters will be granted a 30-day option to purchase up to an additional 588,240 shares of common stock.
Net proceeds from the offering are estimated to be $375.5m, which will be used for research, manufacturing and clinical activities to support its clinical programmes and pre-commercial activities.
Some of the proceeds will also be used for medical affairs, development of commercial initiatives and for the potential launch of AVXS-101 and licensing. Other parts of funds will be assigned for working capital and general corporate purposes.
AzurRx BioPharma Inc has completed the private placement of 851,987 shares at a price of $2.39 a share to raise $2.04m in gross proceeds upon exercise of warrants.
The US-based biopharmaceutical company is involved in the development of recombinant proteins for treating gastrointestinal diseases.
Chinese biopharmaceutical company Suzhou Zelgen Biosciences Co Ltd has raised CNY400m ($61.82m) in a series B financing round.
Shenzhen Capital Group Co Ltd, Minsheng Life Insurance Co Ltd, and Share Capital, took part in the round, along with a participation of Northern Light Venture Capital Corp and China Youth Finance Network.
The company plans to use funding to support clinical trials of its chemical biologic drugs, and for the clinical trial, and preparation and launch of donafenib tosylate.